Natixis Advisors, L.P. Tg Therapeutics, Inc. Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 43,908 shares of TGTX stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,908
Previous 40,547
8.29%
Holding current value
$1.6 Million
Previous $1.6 Million
1.19%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TGTX
# of Institutions
406Shares Held
92.4MCall Options Held
2.28MPut Options Held
1.78M-
Vanguard Group Inc Valley Forge, PA15.8MShares$577 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$416 Million0.0% of portfolio
-
State Street Corp Boston, MA7.62MShares$278 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.49MShares$127 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY3.05MShares$111 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.3B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...